408 related articles for article (PubMed ID: 33850049)
1. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33850049
[TBL] [Abstract][Full Text] [Related]
2. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Sekssaoui M; Bockaert J; Marin P; Bécamel C
Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
[TBL] [Abstract][Full Text] [Related]
4. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT
Raval NR; Johansen A; Donovan LL; Ros NF; Ozenne B; Hansen HD; Knudsen GM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467676
[TBL] [Abstract][Full Text] [Related]
5. Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice.
Odland AU; Kristensen JL; Andreasen JT
Behav Brain Res; 2021 Mar; 401():113093. PubMed ID: 33359368
[TBL] [Abstract][Full Text] [Related]
6. Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
Takaba R; Ibi D; Yoshida K; Hosomi E; Kawase R; Kitagawa H; Goto H; Achiwa M; Mizutani K; Maeda K; González-Maeso J; Kitagaki S; Hiramatsu M
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3019-3035. PubMed ID: 37874338
[TBL] [Abstract][Full Text] [Related]
7. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
8. Acute psilocybin enhances cognitive flexibility in rats.
Torrado Pacheco A; Olson RJ; Garza G; Moghaddam B
Neuropsychopharmacology; 2023 Jun; 48(7):1011-1020. PubMed ID: 36807609
[TBL] [Abstract][Full Text] [Related]
9. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Carter OL; Hasler F; Pettigrew JD; Wallis GM; Liu GB; Vollenweider FX
Psychopharmacology (Berl); 2007 Dec; 195(3):415-24. PubMed ID: 17874073
[TBL] [Abstract][Full Text] [Related]
10. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
Kometer M; Schmidt A; Jäncke L; Vollenweider FX
J Neurosci; 2013 Jun; 33(25):10544-51. PubMed ID: 23785166
[TBL] [Abstract][Full Text] [Related]
11. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
12. Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice.
Zhao X; Du Y; Yao Y; Dai W; Yin Y; Wang G; Li Y; Zhang L
J Psychopharmacol; 2024 May; 38(5):489-499. PubMed ID: 38680011
[TBL] [Abstract][Full Text] [Related]
13. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
Wulff AB; Nichols CD; Thompson SM
Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
[TBL] [Abstract][Full Text] [Related]
14. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.
Husain MI; Blumberger DM; Castle DJ; Ledwos N; Fellows E; Jones BDM; Ortiz A; Kloiber S; Wang W; Rosenblat JD; Mulsant BH
BJPsych Open; 2023 Jul; 9(4):e134. PubMed ID: 37489299
[TBL] [Abstract][Full Text] [Related]
15. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
Quednow BB; Kometer M; Geyer MA; Vollenweider FX
Neuropsychopharmacology; 2012 Feb; 37(3):630-40. PubMed ID: 21956447
[TBL] [Abstract][Full Text] [Related]
16. Increased global integration in the brain after psilocybin therapy for depression.
Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
[TBL] [Abstract][Full Text] [Related]
17. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
Meccia J; Lopez J; Bagot RC
Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
[TBL] [Abstract][Full Text] [Related]
18. The zebrafish for preclinical psilocybin research.
Syed OA; Tsang B; Gerlai R
Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin--summary of knowledge and new perspectives.
Tylš F; Páleníček T; Horáček J
Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
[TBL] [Abstract][Full Text] [Related]
20. Psychedelic Psychiatry's Brave New World.
Nutt D; Erritzoe D; Carhart-Harris R
Cell; 2020 Apr; 181(1):24-28. PubMed ID: 32243793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
